Colestipol: (Moderate) The bile-acid sequesterant colestipol is well-known to cause drug interactions by binding and decreasing the oral administration of many drugs, which may include interaction with oral tretinoin; to minimize drug interactions, administer other drugs at least 1 hour before or at least 4 to 6 hours after the administration of cholestyramine or colestipol. Patients should take care and use proper techniques to limit sunlight and UV exposure of treated areas. Tranexamic Acid: (Major) Rare cases of fatal thrombotic complications have been reported in patients treated with systemic all-trans retinoic acid (ATRA) or tretinoin and the use of antifibrinolytic agents, like tranexamic acid. Temporary discontinuation or reduction in application frequency may be necessary until the patient is able to tolerate the treatment. Resin deionized water may also contain pathogens and it may inactivate benzalkonium chloride. No specific studies have been done with oral tretinoin and rifampin, however, patients should be closely monitored for decreased clinical effects of tretinoin, ATRA while receiving concomitant therapy. Patients should take care and use proper techniques to limit sunlight and UV exposure of treated areas. 
endobj
Stored tap water should also not be used for dilution since it may contain microorganisms. During the early weeks of treatment, an apparent exacerbation of inflammatory lesions may occur. cream tretinoin pharmacy mometasone furoate hydroquinone 20g geoff tube skin care pharmacygeoff md No specific studies have been done with oral tretinoin and griseofulvin, however, patients should be closely monitored for decreased clinical effects of tretinoin, ATRA while receiving concomitant therapy. Patients should take care and use proper techniques to limit sunlight and UV exposure of treated areas. Penicillamine: (Major) Do not use penicillamine with antineoplastic agents due to the increased risk of developing severe hematologic and renal toxicity. No specific studies have been done with oral tretinoin and cyclosporine, however, patients should be closely monitored for tretinoin toxicity while receiving concomitant therapy. Erythromycin; Sulfisoxazole: (Moderate) Erythromycin may decrease the CYP450 metabolism of tretinoin, ATRA, potentially resulting in increased plasma concentrations of tretinoin, ATRA. No specific studies have been done with oral tretinoin and erythromycin, however, patients should be closely monitored for tretinoin toxicity while receiving concomitant therapy. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure to SARS-CoV-2 virus after receiving the vaccine. skin 
Porfimer: (Major) Avoid coadministration of porfimer with retinoids due to the risk of increased photosensitivity. Rifapentine: (Moderate) Rifapentine may increase the CYP450 metabolism of tretinoin, ATRA, potentially resulting in decreased plasma concentrations of tretinoin, ATRA. Patients who may have considerable sun exposure due to their occupation and those patients with inherent sensitivity to sunlight should exercise particular caution when using topical tretinoin. "AtA0qCH0 O@
&FFF*> K<
Chlorthalidone; Clonidine: (Moderate) A manufacturer of topical tretinoin states that tretinoin, ATRA should be administered with caution in patients who are also taking drugs known to be photosensitizers, such as thiazide diuretics, as concomitant use may augment phototoxicity. Separate multiple email address with a comma. Tretinoin; Benzoyl Peroxide: (Moderate) Benzoyl peroxide can potentiate the skin irritation caused by topical tretinoin. Wash hands immediately after applying.Gel: Apply lightly to the affected area. Dipyridamole: (Moderate) An additive risk of bleeding may occur when platelet inhibitors are used with agents that cause clinically significant thrombocytopenia including antineoplastic agents, such as tretinoin. Patients should take care and use proper techniques to limit sunlight and UV exposure of treated areas. Codeine; Promethazine: (Moderate) A manufacturer of topical tretinoin states that tretinoin, ATRA should be administered with caution in patients who are also taking drugs known to be photosensitizers, such as phenothiazines, as concomitant use may augment phototoxicity. Patients should take care and use proper techniques to limit sunlight and UV exposure of treated areas. retin 20gm prescriptiongiant Concurrent application of these agents on areas treated with tretinoin should be avoided. 'W}%eu^p@D W1abG:^vG5dj h1e/>kGl2kpe(ARk[9.4w|qMN0nyl/Um=SZV%g'/Npyu9[gi>Ya QNK/dY-:x'*r/p. Frequency of application should be closely monitored by careful observation of the clinical response and skin tolerance; efficacy has not been established for less than once daily application frequency. Rifabutin: (Moderate) Rifabutin may increase the CYP450 metabolism of tretinoin, ATRA, potentially resulting in decreased plasma concentrations of tretinoin, ATRA. To decrease side effects, some studies have applied tretinoin twice weekly instead of daily. Captopril; Hydrochlorothiazide, HCTZ: (Moderate) A manufacturer of topical tretinoin states that tretinoin, ATRA should be administered with caution in patients who are also taking drugs known to be photosensitizers, such as thiazide diuretics, as concomitant use may augment phototoxicity. Patients should take care and use proper techniques to limit sunlight and UV exposure of treated areas. Patients should take care and use proper techniques to limit sunlight and UV exposure of treated areas. Avoid ocular exposure, including eyelids, and contact with the mouth, angles of the nose, and mucous membranes. To minimize drug interactions, administer other drugs at least 1 hour before or at least 4 to 6 hours after the administration of cholestyramine. Qf Ml@DEHb!(`HPb0dFJ|yygs{. Tuberculin Purified Protein Derivative, PPD: (Moderate) Immunosuppressives may decrease the immunological response to tuberculin purified protein derivative, PPD. Therapy should be discontinued 30 days after remission or after 90 days of treatment, whichever occurs first. Patients receiving oral tretinoin should be managed in facilities equipped and staffed with adequate laboratory and supportive medical services to monitor for drug toxicity and to care for patients compromised by these toxicities, including respiratory insufficiency. We do not record any personal information entered above. 5-iZw)hDIC)7}q{s]wq#gX67pF@4`H
'Ih;5;$MxyG]eY_pP58u])Y (Pxa=;%PuUY>n!cglI&N[
9`3tF37. Anagrelide: (Moderate) An additive risk of bleeding may occur when platelet inhibitors are used with agents that cause clinically significant thrombocytopenia including antineoplastic agents, such as tretinoin. There is no expected difference in the systemic absorption of tretinoin from the microsphere formulation. Fludrocortisone: (Minor) Because systemically administered corticosteroids exhibit immunosuppressive effects when given in high doses and/or for extended periods, additive effects may be seen with other immunosuppressives or antineoplastic agents. Isoniazid, INH; Pyrazinamide, PZA; Rifampin: (Moderate) Rifampin may increase the CYP450 metabolism of tretinoin, ATRA, potentially resulting in decreased plasma concentrations of tretinoin, ATRA. In patients receiving orally-administered retinoids along with orlistat, close monitoring is recommended. Hydantoins: (Moderate) Concurrent oral tretinoin therapy with drugs that are inducers of the hepatic cytochrome P450 enzyme system like the hydantoin anticonvulsants can result in significant decreases in serum tretinoin levels, a CYP450 substrate. Patients should take care and use proper techniques to limit sunlight and UV exposure of treated areas. <>/Metadata 125 0 R/ViewerPreferences 126 0 R>>
Concomitant use with other photosensitizing agents may increase the risk of a photosensitivity reaction. Apply a pea-sized amount to cover the entire affected area once daily before bedtime for 24 to 48 weeks. Up to 6 weeks of therapy may be required before improvement is evident. St. John's Wort, Hypericum perforatum: (Moderate) In theory it is possible that additive photosensitizing effects may result from the concomitant use of St. John's wort with other photosensitizing drugs such as retinoids. Aminolevulinic Acid: (Moderate) Tretinoin, ATRA may increase the effects of photosensitizing agents used during photodynamic therapy; concurrent use of photosensitizing agents is often recommended against by the specific photodynamic therapy, or doses of the therapy may require adjustment. Apply only to affected areas; accidental exposure to unaffected skin may cause irritation. Tretinoin resulted in a partial response (PR) rate of 42% in 19 patients with low-risk AIDS-related Kaposi sarcoma in a multicenter, phase II study; additionally, 37% of patients had stable disease (SD). Thyroid hormones: (Moderate) The concomitant use of systemic tretinoin, ATRA and thyroid hormones should be done cautiously due to the potential for increased intracranial pressure and an increased risk of pseudotumor cerebri (benign intracranial hypertension). Up to 7 weeks of therapy may be required before improvement is evident. Topical tretinoin 0.025% to 0.1% applied once daily to affected areas has been used in the treatment of various diseases of keratinization, often in combination with other agents. Apply a thin layer of topical tretinoin to the affected area(s) once daily at bedtime. In addition, a manufacturer of topical tretinoin states that tretinoin, ATRA should be administered with caution in patients who are also taking photosensitizers, such as eravacycline, as concomitant use may augment phototoxicity.
Sitemap 35
